These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 27857062)
1. Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism. Tamura T; Noda H; Joyashiki E; Hoshino M; Watanabe T; Kinosaki M; Nishimura Y; Esaki T; Ogawa K; Miyake T; Arai S; Shimizu M; Kitamura H; Sato H; Kawabe Y Nat Commun; 2016 Nov; 7():13384. PubMed ID: 27857062 [TBL] [Abstract][Full Text] [Related]
2. Lead Optimization and Avoidance of Reactive Metabolite Leading to PCO371, a Potent, Selective, and Orally Available Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist. Nishimura Y; Esaki T; Isshiki Y; Furuta Y; Mizutani A; Kotake T; Emura T; Watanabe Y; Ohta M; Nakagawa T; Ogawa K; Arai S; Noda H; Kitamura H; Shimizu M; Tamura T; Sato H J Med Chem; 2020 May; 63(10):5089-5099. PubMed ID: 32022560 [TBL] [Abstract][Full Text] [Related]
3. Conserved class B GPCR activation by a biased intracellular agonist. Zhao LH; He Q; Yuan Q; Gu Y; He X; Shan H; Li J; Wang K; Li Y; Hu W; Wu K; Shen J; Xu HE Nature; 2023 Sep; 621(7979):635-641. PubMed ID: 37524305 [TBL] [Abstract][Full Text] [Related]
4. Genetic variation in the PTH pathway and bone phenotypes in elderly women: evaluation of PTH, PTHLH, PTHR1 and PTHR2 genes. Tenne M; McGuigan F; Jansson L; Gerdhem P; Obrant KJ; Luthman H; Akesson K Bone; 2008 Apr; 42(4):719-27. PubMed ID: 18280230 [TBL] [Abstract][Full Text] [Related]
5. Ligand-Dependent Effects of Methionine-8 Oxidation in Parathyroid Hormone Peptide Analogues. Daley EJ; Khatri A; Dean T; Vilardaga JP; Zaidi SA; Katritch V; Gardella TJ Endocrinology; 2021 Feb; 162(2):. PubMed ID: 33242090 [TBL] [Abstract][Full Text] [Related]
7. Characterization of PTH/PTHrP receptor in rat duodenum: effects of ageing. Gentili C; Morelli S; de Boland AR J Cell Biochem; 2003 Apr; 88(6):1157-67. PubMed ID: 12647298 [TBL] [Abstract][Full Text] [Related]
8. Actions of the small molecule ligands SW106 and AH-3960 on the type-1 parathyroid hormone receptor. Carter PH; Dean T; Bhayana B; Khatri A; Rajur R; Gardella TJ Mol Endocrinol; 2015 Feb; 29(2):307-21. PubMed ID: 25584411 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical identification of the PTHR1 parathyroid hormone receptor in normal and neoplastic human tissues. Lupp A; Klenk C; Röcken C; Evert M; Mawrin C; Schulz S Eur J Endocrinol; 2010 May; 162(5):979-86. PubMed ID: 20156969 [TBL] [Abstract][Full Text] [Related]
11. Development of a Novel Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist (CH5447240), a Potent and Orally Available Small Molecule for Treatment of Hypoparathyroidism. Nishimura Y; Esaki T; Isshiki Y; Okamoto N; Furuta Y; Kotake T; Watanabe Y; Ohta M; Nakagawa T; Noda H; Shimizu M; Saito H; Tamura T; Sato H J Med Chem; 2018 Jul; 61(14):5949-5962. PubMed ID: 29932656 [TBL] [Abstract][Full Text] [Related]
12. Impaired Immune Function in Patients With Chronic Postsurgical Hypoparathyroidism: Results of the EMPATHY Study. Puliani G; Hasenmajer V; Sciarra F; Barbagallo F; Sbardella E; Pofi R; Gianfrilli D; Romagnoli E; Venneri MA; Isidori AM J Clin Endocrinol Metab; 2021 Apr; 106(5):e2215-e2227. PubMed ID: 33484559 [TBL] [Abstract][Full Text] [Related]
13. Functional analysis of a type 1 parathyroid hormone receptor intracellular tail mutant [KRK(484-6)AAA]: effects on second messenger generation and cellular targeting. Patterson EK; Hodsman AB; Hendy GN; Canaff L; Bringhurst FR; Fraher LJ Bone; 2010 Apr; 46(4):1180-7. PubMed ID: 20006743 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study. Clarke BL; Kay Berg J; Fox J; Cyran JA; Lagast H Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860 [TBL] [Abstract][Full Text] [Related]
16. Repurposing a novel parathyroid hormone analogue to treat hypoparathyroidism. Krishnan V; Ma YL; Chen CZ; Thorne N; Bullock H; Tawa G; Javella-Cauley C; Chu S; Li W; Kohn W; Adrian MD; Benson C; Liu L; Sato M; Zheng W; Pilon AM; Yang NN; Bryant HU Br J Pharmacol; 2018 Jan; 175(2):262-271. PubMed ID: 28898923 [TBL] [Abstract][Full Text] [Related]
17. The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. Sikjaer T; Rejnmark L; Rolighed L; Heickendorff L; Mosekilde L; J Bone Miner Res; 2011 Oct; 26(10):2358-70. PubMed ID: 21773992 [TBL] [Abstract][Full Text] [Related]
18. Bone and parathyroid inhibitory effects of S-2(3-aminopropylamino)ethylphosphorothioic acid. Studies in experimental animals and cultured bone cells. Attie MF; Fallon MD; Spar B; Wolf JS; Slatopolsky E; Goldfarb S J Clin Invest; 1985 Apr; 75(4):1191-7. PubMed ID: 2985652 [TBL] [Abstract][Full Text] [Related]
19. Discovery of a small molecule antagonist of the parathyroid hormone receptor by using an N-terminal parathyroid hormone peptide probe. Carter PH; Liu RQ; Foster WR; Tamasi JA; Tebben AJ; Favata M; Staal A; Cvijic ME; French MH; Dell V; Apanovitch D; Lei M; Zhao Q; Cunningham M; Decicco CP; Trzaskos JM; Feyen JH Proc Natl Acad Sci U S A; 2007 Apr; 104(16):6846-51. PubMed ID: 17428923 [TBL] [Abstract][Full Text] [Related]
20. Development of Potent, Protease-Resistant Agonists of the Parathyroid Hormone Receptor with Broad β Residue Distribution. Cheloha RW; Chen B; Kumar NN; Watanabe T; Thorne RG; Li L; Gardella TJ; Gellman SH J Med Chem; 2017 Nov; 60(21):8816-8833. PubMed ID: 29064243 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]